Jump to main content
Jump to site search

Issue 1, 2012
Previous Article Next Article

A self-immolative dendritic glucuronide prodrug of doxorubicin

Author affiliations

Abstract

The first self-immolative dendritic glucuronide prodrug of doxorubicin was studied with the aim to target β-glucuronidase overexpressed in the microenvironment of numerous tumors. This compound includes a chemical amplifier programmed to release two molecules of doxorubicin after a single enzymatic activation step. Upon β-glucuronidase activation, the dendritic prodrug was twice more toxic than its monomeric counterpart against H661 lung cancer cells.

Graphical abstract: A self-immolative dendritic glucuronide prodrug of doxorubicin

Back to tab navigation

Supplementary files

Publication details

The article was received on 29 Jul 2011, accepted on 21 Sep 2011 and first published on 19 Oct 2011


Article type: Concise Article
DOI: 10.1039/C1MD00193K
Citation: Med. Chem. Commun., 2012,3, 68-70
  •   Request permissions

    A self-immolative dendritic glucuronide prodrug of doxorubicin

    M. Grinda, J. Clarhaut, B. Renoux, I. Tranoy-Opalinski and S. Papot, Med. Chem. Commun., 2012, 3, 68
    DOI: 10.1039/C1MD00193K

Search articles by author

Spotlight

Advertisements